41-50 of 77 results

Special Report: Understanding the opportunities and navigating the legal frameworks of distributed ledger technology and blockchain
Insight 17 Jun 2016

Authored by a multidisciplinary team from Allens Blockchain Reaction is designed to assist business stakeholders decision makers and in-house counsel across a variety of sectors to understand the technology and how it is being used as well as navigate the regulatory and legal opportunities and ...

High Court unanimously finds isolated genetic material not patentable
Insight 08 Oct 2015

In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...

ACCC's Enforcement and Compliance priorities for 2017
Insight 27 Feb 2017

Criminal cartels unfair contract terms consumer guarantees and the health construction and agriculture sectors are some of the ACCCs key enforcement and compliance priorities for 2017 ACCC Chairman Rod Sims released the ACCCs 2017 Compliance and Enforcement Policy on Friday 24 February 2017 ...

Allens advises financiers on Icon Group acquisition
News 25 May 2017

Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group. The acquisition, ...

Allens lends a hand to Global Health
News 16 Mar 2015

Allens has advised the Global Health Investment Fund ( GHIF ), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately ...

Allens advises Archer Capital on sale of Healthe Care
News 08 Dec 2015

Allens has advised Archer Capital on its proposed divestment of private hospital business Healthe Care to China's Luye Medical Group. Healthe Care is Australia's third largest private hospital ...

Unexpected risks of the IoT revolution: Cyber security in medical devices
Insight 16 Oct 2017

In late August 2017 the US Food and Drug Administration recalled 465000 Abbott Laboratories pacemakers due to cyber security vulnerabilities Although this was the first time that the FDA had recalled a medical device because of cyber concerns they have been alive to the significant risk that a cyber ...

Competition news
Insight 14 Sep 2017

In Touch looks at what's been happening in Competition this month and what it means for your business ...

Assessment of biosimilars - Is Australia leading, following or going its own way?
Insight 26 Oct 2016

The ongoing lack of certainty about what is required to obtain biosimilar registration in Australia extends to three key issues - Comparability is the new product sufficiently similar to permit it to rely on the reference products safety and efficacy data Extrapolation for which of the indications ...

Refine